

Panel 7: Perspectives on PrEP Implementation

Public Sector Payor Perspective

Claire Foreman, London Specialised
Commissioning Group

Tuesday 12 June 2012



Public Payor Perspective

PrEP in context of

- NHS free at point of use
- Promoting public health and equity AND meeting local needs
- Services commissioned on basis of evidence and NICE approval for access to drugs
- Acting as the agents of patients AND the tax payer
- 'Nicholson Challenge' of £20 billion savings by 2015

As the agent of patients...

- Does it work? Will it improve outcomes for individuals?
- Do the benefits outweigh the risk of harm?
- Does it add value to patient choice and experience?
- Is it a realistic choice for patients? What are the responsibilities of patients?
- How will we define entitlement?
- Where will it be available?
- How will we monitor implementation?

As the agent of the taxpayer...

- Is it a priority? Does it fit with health policy?
- Does it add value to individual and public health?
- Is it a realistic option? How does it compare to the options we already have?
- What are the cost implications now and for the future?
- What might be the unintended consequences?
- Who will pay and how?
- Does it meet the QIPP (Quality Innovation Productivity and Prevention) agenda?

PrEP - other thoughts and questions ...

- Are we in the lab or the consulting room?
- Will this expand or constrain HIV prevention efforts?
- Is this the right priority?
- If it does add value, when will we know?
- To what extent should the cost of drugs reflect their use?